



Ain Shams University
Faculty of Medicine

Recent Advances In The Management Of Carcinoid Tumors

Essay
Submitted for partial fulfillment of
Master Degree in Radiation Oncology and Nuclear Medicine

By
DALIA MAGDY ELSHEIKH
M.B.,B.Ch.

Supervised by
Prof. Dr. Soheir Helmy Mahmoud
Professor of Radiation Oncology and Nuclear Medicine
Faculty of Medicine, Ain shams University

Dr. Amro Lotfy Farag
Assistant Professor of Radiation Oncology and Nuclear Medicine
Faculty of Medicine, Ain shams University

Dr. Dalia Abdelghany El Khodary
Lecturer of Radiation Oncology and Nuclear Medicine
Faculty of Medicine, Ain shams University

Faculty of Medicine
Ain shams University
2009-2010

Acknowledgement

First I would like to thank *Allah* the most gracious, the most merciful for all his blessings and bounties one of which is the completion of this work and many others that I feel grateful for.

Second, I would like to express my deepest gratitude for ***Professor Dr. Soheir Helmy Mahmoud, (professor of clinical oncology and nuclear medicine, Ain Shams university)*** for her overwhelming support. Her meticulous observation and supervision allowed for this work to come to light in its best form possible.

Similarly, I hold all gratitude for ***Dr. Amro Lotfy Farag, (assistant professor of clinical oncology and nuclear medicine, Ain Shams university)*** for his sincere instructions and guidance. I thank you for your time and effort.

Likewise, I would like to show all appreciation for ***Dr. Dalia Abdelghany Elkhodary, (lecturer of clinical oncology and nuclear medicine, Ain Shams university)*** for her valuable advice and for her sincere dedication and keenness to fulfill and thoroughly revise this work.

Last but not least I would like to thank all the staff members of the department of clinical oncology and nuclear medicine of Ain shams university for their contribution in my education.

Dedication

To my inspiring family;

my father and mother,

my husband,

my sister and brothers,

for their everlasting support and love.

Table of contents

Title	Page
List of tables	II
List of figures	III
List of Abbreviations	V
01-Introduction	1
02-Epidemiology	7
03-Pathophysiology	11
04-Clinical Picture	24
05-Diagnosis	37
06-Treatment	56
07-Prognosis	85
08-Summary and conclusion	97
09-References	101
10-Arabic Summary	

List of tables

Table (1)	Characteristics of carcinoid tumors (classified according to embryological origin).	13
Table (2)	Characteristics of carcinoid tumors (classified according to site).	14
Table (3)	Circulating peptides in carcinoid disease: percentage positivity.	43

List of figures

Figure(1)	Distribution of gastrointestinal carcinoid tumors by primary tumor site. (Jonathan et al., 2008).	8
Figure(2)	Pathways of tryptophan and serotonin metabolism in the carcinoid cell. Patients with the carcinoid syndrome have increased levels of 5-HIAA excretion in the urine and serotonin uptake by platelets; urinary serotonin excretion is either normal or slightly increased.	37
Figure(3)	Octreoscan in malignant metastatic neuroendocrine tumor.	48
Figure(4)	Enhanced resolution of metastases with 96 vs. 24 h octreoscan.	49
Figure(5)	CT scan of metastatic midgut NET demonstrating scattered malignant lymph nodes.	50
Figure(6)	CT (A) and MRI (B) scans of metastatic NETs arising from the midgut, demonstrating an extensive and desmoplastic response binding the mesentery .	52

Figure(7)	A, T1 weighted of hepatic metastasis in a patient with metastatic NET. B, T2 weighted MRI in the same patient.	53
Figure(8)	A comparison of CT (axial; left), conventional (axial; middle), and post mangafodopir (Teslascan) (coronal; right) MRI scans in a patient with hepatic metastases from a midgut NET.	54

List of Abbreviations

111-In	Indium -111
177 LU	Lutetium -177
5- FU	5-fluorouracil
5-HIAA	5-Hydroxyindoleacetic acid
5-HT	5-hydroxytryptamine
5-HTP	5-hydroxytryptophan
90-Y	Yttrium -90
ACTH	Adrenocorticotrophic hormone
APUDomas	Amine precursor uptake decarboxylase
bFGF	basic fibroblast growth factor
CAG A	Chronic atrophic gastritis type A
CgA	Chromogranin A
CGRP	Calcitonin gene-related peptide
CSF-1R	Colony-stimulating factor receptor
CT	Computed Tomography
EC cell	Enterochromaffin cell
ECL	Enterochromaffin like
ECOG	Eastern oncology cooperative group
EGFR	Epidermal growth factor receptor
FGFR1	Fibroblast growth factor receptor

GI	Gastrointestinal
GRP	Gastrin releasing peptide
HAE	Hepatic Artery Embolization
HPA	High powered field
IGF	Insulin-like growth factor
IGF-1R	Insulin-like growth factor receptor
IM	Intramuscular
INFa	Interferon alpha
IV	Intravenous
KIT	Stem cell factor receptor
LGNET	Low grade neuroendocrinal tumors
MAO	Monoamine oxidase
MEN 1	Multiple endocrine neoplasia (type 1)
MIBG	Metaiodobenzylguanidin
MRI	Magnetic Resonance Imaging
mTOR	Mammalian target of rapamycin
N peptide K	Neuropeptide K
NCCN	National comprehensive cancer network
NE T	Neuroendocrine Tumors
NSE	Neuron specific enolase
OLT	Orthotopic liver transplantation
PDGF	Platelet derived growth factor

PDGFR	Platelet derived growth factor receptor
PET	Positron emission tomography
PYY	Peptide YY
RFA	Radiofrequency ablation
RT	Radiotherapy
SEER	Surveillance, Epidemiology and End Results
SPECT	single photon emission computed tomography
SRS	Somatostatin receptor scintigraphy
SSTRs	Somatostatin receptors
SWOG	Southwest oncology group
TGF	Transforming growth factor
TKs	Tyrosine kinases
VEGF	vascular endothelial growth factor
WHO	World Health Organization

Abbreviations

111-In	Indium -111
177 LU	Lutetium -177
5- FU	5-fluorouracil
5-HIAA	5-Hydroxyindoleacetic acid
5-HT	5-hydroxytryptamine
5-HTP	5-hydroxytryptophan
90-Y	Yttrium -90
ACTH	Adrenocorticotrophic hormone
APUDomas	Amine precursor uptake decarboxylase
bFGF	basic fibroblast growth factor
CAG A	Chronic atrophic gastritis type A
CgA	Chromogranin A
CGRP	Calcitonin gene-related peptide
CSF-1R	Colony-stimulating factor receptor
CT	Computed Tomography
EC cell	Enterochromaffin cell
ECL	Enterochromaffin like
ECOG	Eastern oncology cooperative group
EGFR	Epidermal growth factor receptor
FGFR1	Fibroblast growth factor receptor

GI	Gastrointestinal
GRP	Gastrin releasing peptide
HAE	Hepatic Artery Embolization
HPA	High powered field
IGF	Insulin-like growth factor
IGF-1R	Insulin-like growth factor receptor
IM	Intramuscular
INFα	Interferon alpha
IV	Intravenous
KIT	Stem cell factor receptor
LGNET	Low grade neuroendocrinal tumors
MAO	Monoamine oxidase
MEN 1	Multiple endocrine neoplasia (type 1)
MIBG	Metaiodobenzylguanidin
MRI	Magnetic Resonance Imaging
mTOR	Mammalian target of rapamycin
N peptide K	Neuropeptide K
NCCN	National comprehensive cancer network
NE T	Neuroendocrine Tumors
NSE	Neuron specific enolase
OLT	Orthotopic liver transplantation
PDGF	Platelet derived growth factor

PDGFR	Platelet derived growth factor receptor
PET	Positron emission tomography
PYY	Peptide YY
RFA	Radiofrequency ablation
RT	Radiotherapy
SEER	Surveillance, Epidemiology and End Results
SPECT	single photon emission computed tomography
SRS	Somatostatin receptor scintigraphy
SSTRs	Somatostatin receptors
SWOG	Southwest oncology group
TGF	Transforming growth factor
TKs	Tyrosine kinases
VEGF	vascular endothelial growth factor
WHO	World Health Organization

List of figures

Figure(1)	Distribution of gastrointestinal carcinoid tumors by primary tumor site. (Jonathan et al., 2008).	
Figure(2)	Pathways of tryptophan and serotonin metabolism in the carcinoid cell. Patients with the carcinoid syndrome have increased levels of 5-HIAA excretion in the urine and serotonin uptake by platelets; urinary serotonin excretion is either normal or slightly increased.	
Figure(3)	Octreoscan in malignant metastatic neuroendocrine tumor.	
Figure(4)	Enhanced resolution of metastases with 96 vs. 24 h octreoscan.	
Figure(5)	CT scan of metastatic midgut NET demonstrating scattered malignant lymph nodes.	
Figure(6)	CT (A) and MRI (B) scans of metastatic NETs arising from the midgut, demonstrating an extensive and desmoplastic response binding the mesentery .	

Figure(7)	A, T1 weighted of hepatic metastasis in a patient with metastatic NET. B, T2 weighted MRI in the same patient.	
Figure(8)	A comparison of CT (axial; left), conventional (axial; middle), and post mangafodopir (Teslascan) (coronal; right) MRI scans in a patient with hepatic metastases from a midgut NET.	